News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Moderna discontinues mRNA-1647 development for congenital CMV after Phase 3 trial failure, but continues in bone marrow transplant patients with no impact on financial guidance. Details on the study outcomes and company's future plans -
-
-
-
-
-